The company seeks to identify, manage, and mitigate risks to its business, recognizing that uncertainties and risks are difficult to predict and many are outside of its control. The company has robust business continuity plans in place across its global supply chain network to help mitigate the impact of COVID-19, although these efforts may not completely prevent adverse effects on its business. The company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations, and commercial capabilities. The company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory at major distribution centers away from high-risk areas to ensure adequate and effective distribution. The company has considered various internal and external factors in assessing the potential impact of COVID-19 on its business and financial results. The company’s high-quality credit rating allows superior access to financial capital markets for the foreseeable future, which is crucial for maintaining operational continuity. The company has entered into a series of contract manufacturing arrangements for vaccine production with third-party organizations, providing supplemental commercial capacity for vaccine production. The company’s operating model has been instrumental in preparing for events like COVID-19, ensuring that the majority of patient and consumer needs remain uninterrupted. The company is committed to creating value by developing accessible, high-quality, innovative products and services, and it invests significantly in research and development to address evolving healthcare needs. The company’s diverse workforce is empowered to lead with agility and urgency, enabling it to adapt to changing market demands. The company’s strategic initiatives include focusing resources and increasing investments in critical capabilities necessary to manufacture and supply its product portfolio of the future, enhancing agility and driving growth. The company has faced significant competition in all operating segments, which requires continuous innovation and adaptation to maintain competitive advantage. The company actively monitors global legislative efforts to combat the impact of COVID-19 on economies and the sectors in which it participates. The company’s ability to foresee, confront, and benefit from sudden disruptive changes is essential for its survival and growth. The company recognizes that the ongoing global health crisis may lead to changes in consumer behavior and spending patterns, which could impact its business operations. The company’s extensive information security and cybersecurity measures are designed to protect its operations and maintain organizational resilience against external threats. The company continues to assess the evolving landscape of risks, including those related to product safety and regulatory compliance, which are critical to its organizational health and operational effectiveness. The company’s commitment to sustainability and responsible pricing practices reflects its understanding of the pressures and demands of the healthcare market. The company’s strategic response to environmental disruptions and operational challenges is essential for maintaining its performance and ensuring long-term resilience.